Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HIMS NYSE:NVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$35.75-1.2%$28.92$13.74▼$70.43$8.08B2.3529.05 million shs415,341 shsNVONovo Nordisk A/S$48.83-1.6%$45.08$35.12▼$71.79$217.53B0.7719.23 million shs309,776 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health-5.62%+4.77%+37.83%+86.81%-25.14%NVONovo Nordisk A/S+0.64%+3.50%+15.54%+31.84%-28.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$35.75-1.2%$28.92$13.74▼$70.43$8.08B2.3529.05 million shs415,341 shsNVONovo Nordisk A/S$48.83-1.6%$45.08$35.12▼$71.79$217.53B0.7719.23 million shs309,776 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health-5.62%+4.77%+37.83%+86.81%-25.14%NVONovo Nordisk A/S+0.64%+3.50%+15.54%+31.84%-28.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHIMSHims & Hers Health 2.13Hold$30.63-15.34% DownsideNVONovo Nordisk A/S 2.17Hold$65.5632.19% UpsideCurrent Analyst Ratings BreakdownLatest HIMS and NVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/6/2026NVONovo Nordisk A/S HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold7/1/2026HIMSHims & Hers Health Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $40.007/1/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$25.00 ➝ $36.006/19/2026NVONovo Nordisk A/S Nordea Equity ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy6/17/2026HIMSHims & Hers Health BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$29.00 ➝ $39.006/8/2026HIMSHims & Hers Health Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/26/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$28.00 ➝ $25.005/22/2026HIMSHims & Hers Health UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$23.005/22/2026HIMSHims & Hers Health Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$18.00 ➝ $23.005/19/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$30.00 ➝ $28.005/13/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$32.00 ➝ $30.00(Data available from 7/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHIMSHims & Hers Health$2.35B3.57$0.79 per share45.74$2.38 per share15.20NVONovo Nordisk A/S$46.80B4.73$4.72 per share10.51$6.58 per share7.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHIMSHims & Hers Health$128.37M-$0.09N/A69.59107.73-0.56%6.10%1.52%8/10/2026 (Estimated)NVONovo Nordisk A/S$15.51B$4.2611.6415.174.4937.23%63.31%22.19%8/5/2026 (Estimated)Latest HIMS and NVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026NVONovo Nordisk A/S$0.82N/AN/AN/A$11.00 billionN/A5/11/2026Q1 2026HIMSHims & Hers Health$0.04-$0.40-$0.44-$0.40$616.84 million$608.10 million5/6/2026Q1 2026NVONovo Nordisk A/S$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHIMSHims & Hers HealthN/AN/AN/AN/AN/ANVONovo Nordisk A/S$1.753.53%+21.74%41.08%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHIMSHims & Hers Health2.181.691.56NVONovo Nordisk A/S0.590.790.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHIMSHims & Hers Health63.52%NVONovo Nordisk A/S11.54%Insider OwnershipCompanyInsider OwnershipHIMSHims & Hers Health11.76%NVONovo Nordisk A/S0.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHIMSHims & Hers Health2,442231.46 million204.24 millionOptionableNVONovo Nordisk A/S69,5054.47 billion4.46 billionOptionableHIMS and NVO HeadlinesRecent News About These CompaniesMAHE and Novo Nordisk GBS expand collaboration in pharmacometrics1 hour ago | thehindubusinessline.comNovo Nordisk signs pact with Vivani for long-lasting semaglutide implant1 hour ago | pharmaceutical-technology.comPLeading bank backs European pharma as the cleaner alternative to the AI trade1 hour ago | proactiveinvestors.co.uk3 Reasons to Buy Novo Nordisk StockJuly 7 at 5:06 PM | fool.comPfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?July 7 at 12:06 PM | finance.yahoo.comWhy This Novo Nordisk Rival Just Soared Near A Profit-Taking ZoneJuly 7 at 12:06 PM | finance.yahoo.com2 Dirt Cheap Healthcare Stocks to Buy in JulyJuly 7 at 8:30 AM | 247wallst.comAs Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner (NVO)...July 6 at 2:20 PM | marketbeat.comNovo Nordisk Updates DKK 15 Billion Share Buyback as Treasury Stake Reaches 0.9%July 6 at 7:30 AM | tipranks.comQRG Capital Management Inc. Has $5.23 Million Stock Position in Novo Nordisk A/S $NVOJuly 6 at 5:27 AM | marketbeat.comTrump’s FDA May Soon Throw Its Weight Behind Peptides. Should You Buy In?July 5 at 7:16 AM | finance.yahoo.comY Intercept Hong Kong Ltd Grows Stake in Novo Nordisk A/S $NVOJuly 5 at 6:23 AM | marketbeat.comHow Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?July 5 at 1:28 AM | fool.comNovo Nordisk: The Stock Price Is Only Beginning To Catch Up With Business FundamentalsJuly 4, 2026 | seekingalpha.com327,357 Shares in Novo Nordisk A/S $NVO Purchased by Simplify Asset Management Inc.July 4, 2026 | marketbeat.comNovo Nordisk (NVO) Stock May Be 48% Undervalued On Medicare GLP 1 CoverageJuly 3, 2026 | finance.yahoo.comCan Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?July 3, 2026 | zacks.comNovo Nordisk (CPSE:NOVO B) Stock Looks Undervalued As Broader Checks Stay SupportiveJuly 3, 2026 | finance.yahoo.comNovo Nordisk (NVO) Is At The Center Of A Fast Growing Diabetes Drug MarketJuly 3, 2026 | finance.yahoo.comNovo Nordisk AS (NVO) Stock Up 3.4% and Still Undervalued -- GF Score: 76/100July 2, 2026 | gurufocus.comLilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?July 2, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 2026As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the WinnerBy Jordan Chussler | July 6, 2026HIMS and NVO Company DescriptionsHims & Hers Health NYSE:HIMS$35.75 -0.42 (-1.15%) As of 09:40 AM Eastern This is a fair market value price provided by Massive. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Novo Nordisk A/S NYSE:NVO$48.83 -0.81 (-1.63%) As of 09:40 AM Eastern This is a fair market value price provided by Massive. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Apple and Broadcom Forge a Decade-Long Silicon Fortress SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity Industrials Are Leading in 2026, But These ETFs Take Different Routes Palantir's CEO Just Called Out OpenAI and Anthropic Drone Stocks Are Down, But Defense Backlogs Tell a Different Story Silicon Starvation: Amazon Feasts on Legacy GPUs Stacking Chips: The Hidden Supply Shock Fueling Intel Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
